<?xml version='1.0' encoding='utf-8'?>
<document id="31498564"><sentence text="Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer."><entity charOffset="75-86" id="DDI-PubMed.31498564.s1.e0" text="Osimertinib" /><entity charOffset="91-102" id="DDI-PubMed.31498564.s1.e1" text="Simvastatin" /><pair ddi="false" e1="DDI-PubMed.31498564.s1.e0" e2="DDI-PubMed.31498564.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31498564.s1.e0" e2="DDI-PubMed.31498564.s1.e1" /></sentence><sentence text="A phase I, open-label study (NCT02197234) assessed the effects of osimertinib on simvastatin exposure in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer and disease progression post-EGFR tyrosine kinase inhibitor treatment"><entity charOffset="66-77" id="DDI-PubMed.31498564.s2.e0" text="osimertinib" /><entity charOffset="81-92" id="DDI-PubMed.31498564.s2.e1" text="simvastatin" /><entity charOffset="237-245" id="DDI-PubMed.31498564.s2.e2" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.31498564.s2.e0" e2="DDI-PubMed.31498564.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31498564.s2.e0" e2="DDI-PubMed.31498564.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31498564.s2.e0" e2="DDI-PubMed.31498564.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31498564.s2.e1" e2="DDI-PubMed.31498564.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31498564.s2.e1" e2="DDI-PubMed.31498564.s2.e2" /></sentence><sentence text=" Here, we report on a retrospective analysis of two patients (patients 1 and 2) who had liver metastases and high simvastatin exposure prior to osimertinib treatment, which changed following treatment"><entity charOffset="114-125" id="DDI-PubMed.31498564.s3.e0" text="simvastatin" /><entity charOffset="144-155" id="DDI-PubMed.31498564.s3.e1" text="osimertinib" /><pair ddi="false" e1="DDI-PubMed.31498564.s3.e0" e2="DDI-PubMed.31498564.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31498564.s3.e0" e2="DDI-PubMed.31498564.s3.e1" /></sentence><sentence text=" Patients received single oral doses of simvastatin 40 mg on day (D) 1 and D31, and osimertinib 80 mg once daily on D3-32"><entity charOffset="40-51" id="DDI-PubMed.31498564.s4.e0" text="simvastatin" /></sentence><sentence text=" At baseline, both patients had abnormal liver function tests (LFTs; Child-Pugh scores of 6 and 8, respectively), significant liver metastasis, and, after a single simvastatin dose, had higher (~ 10-fold) exposure compared with all other patients"><entity charOffset="164-175" id="DDI-PubMed.31498564.s5.e0" text="simvastatin" /></sentence><sentence text=" Following 31 days of continuous osimertinib treatment, simvastatin exposures (area under the plasma concentration-time curve from zero to infinity (AUC) and maximum plasma concentration (Cmax )) and LFTs, such as alanine transaminase, aspartate aminotransferase, and bilirubin normalized to population mean values"><entity charOffset="33-44" id="DDI-PubMed.31498564.s6.e0" text="osimertinib" /><entity charOffset="56-67" id="DDI-PubMed.31498564.s6.e1" text="simvastatin" /><entity charOffset="214-221" id="DDI-PubMed.31498564.s6.e2" text="alanine" /><entity charOffset="236-245" id="DDI-PubMed.31498564.s6.e3" text="aspartate" /><entity charOffset="268-277" id="DDI-PubMed.31498564.s6.e4" text="bilirubin" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e0" e2="DDI-PubMed.31498564.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e0" e2="DDI-PubMed.31498564.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e0" e2="DDI-PubMed.31498564.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e0" e2="DDI-PubMed.31498564.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e0" e2="DDI-PubMed.31498564.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e1" e2="DDI-PubMed.31498564.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e1" e2="DDI-PubMed.31498564.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e1" e2="DDI-PubMed.31498564.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e1" e2="DDI-PubMed.31498564.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e2" e2="DDI-PubMed.31498564.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e2" e2="DDI-PubMed.31498564.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e2" e2="DDI-PubMed.31498564.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e3" e2="DDI-PubMed.31498564.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31498564.s6.e3" e2="DDI-PubMed.31498564.s6.e4" /></sentence><sentence text=" Additionally, ~ 50% and ~ 80% reductions in liver metastases were observed on computed tomography scans in patients 1 and 2, respectively" /><sentence text=" High simvastatin exposure on D1 likely resulted from impairment of hepatic first pass metabolism due to liver metastases"><entity charOffset="6-17" id="DDI-PubMed.31498564.s8.e0" text="simvastatin" /></sentence><sentence text=" Reduction in hepatic disease burden due to osimertinib treatment likely resulted in liver function returning to normal levels"><entity charOffset="44-55" id="DDI-PubMed.31498564.s9.e0" text="osimertinib" /></sentence><sentence text="" /></document>